CLAIMS

1. A pharmaceutical composition comprising 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof, ~~a sweetener~~ sucralose, and two or more sugars and/or sugar alcohols~~.~~

~~2. The pharmaceutical composition according to claim 1, wherein the sweetener is one, or two or more compounds selected from the group consisting of saccharin, acesulfame potassium, aspartame, and sucralose, and a mixture thereof.~~

~~3. The pharmaceutical composition according to claim 1 or 2, wherein the sweetener is sucralose.~~

~~4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the sugars are disaccharides and the sugar alcohols have 6 or 12 carbon atoms.~~

~~5. The pharmaceutical composition according to any one of claims 1 to 4~~,

wherein the two or more sugars and/or sugar alcohols comprise:

mannitol; and

~~are selected from~~ one of the group consisting of ~~mannitol,~~ isomalt hydrate, maltitol, sorbitol, ~~lactose,~~ sucrose, and trehalose~~,~~; and ~~a mixture thereof~~

wherein the pharmaceutical composition is a tablet.

~~6. The pharmaceutical composition according to any one of claims 1 to 5, wherein one of the two or more sugars and/or sugar alcohols is mannitol.~~

~~7. The pharmaceutical composition according to any one of claims 1 to 5, wherein one of the two or more sugars and/or sugar alcohols is selected from the group consisting of isomalt hydrate, maltitol, sorbitol, sucrose, and trehalose.~~

~~8~~2. The pharmaceutical composition according to ~~any one of claims 1 to 5~~ claim 1, wherein one of the two or more sugars and/or sugar alcohols is isomalt hydrate.

~~9~~3. The pharmaceutical composition according to claim ~~7~~1 or ~~8~~2, wherein a content of the isomalt hydrate, maltitol, sorbitol, sucrose, or trehalose described in claim ~~7~~1 or ~~8~~2 with respect to a weight of the pharmaceutical composition is 1% by weight to 20% by weight.

~~10~~4. The pharmaceutical composition according to claim ~~7~~1 or ~~8~~2, wherein the isomalt hydrate, maltitol, sorbitol, sucrose, or trehalose described in claim ~~7~~1 or ~~8~~2 is used as a binder.

~~11~~5. The pharmaceutical composition according to any one of claims 1 to ~~10~~4, wherein the pharmaceutically acceptable salt thereof is a hemifumarate.

~~12. The pharmaceutical composition according to any one of claims 1 to 11, wherein the pharmaceutical composition is solid.~~

~~13~~6. The pharmaceutical composition according to any one of claims 1 to ~~12~~5, further comprising a disintegrating agent.

~~14. The pharmaceutical composition according to claim 12 or 13, wherein the pharmaceutical composition is a tablet.~~

~~15~~7. The pharmaceutical composition according to any one of claims 1 to ~~14~~6, wherein, after storing the pharmaceutical composition according to any one of claims 1 to ~~14~~6 at 40°C and 75% relative humidity for 1 month, a dissolution rate of 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide after 15 minutes from the beginning of a Dissolution Test, a paddle method using 900 mL of 0.1 mol/L hydrochloric acid described in the Japanese Pharmacopoeia, Seventeenth Edition is 85% or more; or
wherein, after storing the pharmaceutical composition according to any one of claims 1 to ~~14~~6 at 40°C and 75% relative humidity for 2 months and/or 3 months, a dissolution rate of 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide after 15 minutes from the beginning of a Dissolution Test, a paddle method using 900 mL of 0.1 mol/L hydrochloric acid described in the Japanese Pharmacopoeia, Seventeenth Edition is 80% or more.

~~16~~8. The pharmaceutical composition according to any one of claims 1 to ~~15~~7, wherein the pharmaceutical composition is dissolved or dispersed in a suitable solvent, and is a solution, suspension, paste, or gel.

~~17~~9. A pharmaceutical composition comprising 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide hemifumarate, mannitol, sucralose, and isomalt hydrate.

~~18. The pharmaceutical composition according to any one of claims 1 to 17 produced by a production method comprising:~~

~~(1) preparing a binder liquid by dispersing or dissolving at least one sugars and/or sugar alcohols in a solvent;~~

~~(2) obtaining a mixture by mixing 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof, a sweetener, and at least one sugars and/or sugar alcohols; and~~

~~(3) spraying or adding the binder liquid obtained in step (1) to the mixture obtained in step (2) to form granules.~~

~~19~~10. A method of producing a pharmaceutical composition comprising 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof, and two or more sugars and/or sugar alcohols, said method comprising:
(1) preparing a binder liquid by dispersing or dissolving at least one sugars and/or sugar alcohols in a solvent;
(2) obtaining a mixture by mixing 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide or a

pharmaceutically acceptable salt thereof, ~~a sweetener~~ sucralose, and at least one sugars and/or sugar alcohols; and

(3) spraying or adding the binder liquid obtained in step (1) to the mixture obtained in step (2) to form granules,

wherein the two or more sugars and/or sugar alcohols comprise:

mannitol; and

one of the group consisting of isomalt hydrate, maltitol, sorbitol, sucrose, and trehalose; and

wherein the pharmaceutical composition is a tablet.